Congress Program

Monday, 30 October


 07:30 Registration 
 08:30 Session I: Opening
 
Welcome to London

Distinguished Speaker, to be announced
Importance of Disease Prevention to the UK and World (invited)
Introduced by Julia Manning, Founding Director, 2020health, UK (Co-Chair)


Importance of Disease Prevention to the UK and World

“Metabesity—What, Why and How”
Alexander FlemingExecutive Chairman and Founder, Kinexum, USA (Co-Chair)

“It’s as much about Economics as Science”
Joseph C. Cook, Jr.
Executive Chairman of the Board & President, NuSirt Biopharma, USA

Overview of the Conference
Lawrence SteinmanGeorge A. Zimmermann Professor and Professor of Pediatrics, Stanford University, USA 
(Co-Chair)                             

  Session II: Overviews of Metabesity Targets
 
Aging, From Hope to Promise in Targeting Aging


Diabetes

Neurodegeneration
Sir John Bell, Regius Professor of Medicine, Oxford University, UK

Cancer 
Ashok VenkitaramanUrsula Zoellner Professor of Cancer Research,University of Cambridge, and Director of the Medical Research Council (MRC) Cancer Unit, UK

10:30
Coffee Break, Poster Viewing and Visit the Exhibition

 11:00 Session III: Metabesity-Related Basic Science
 
NAD Metabolism and Aging
Eric VerdinBuck Institute for Research on Aging, California, USA

Glucose Metabolism as a Modulator of Aß Toxicity
Teresa NiccoliUniversity College London, UK

Targeting Metabolic Pathways and Delaying Aging in Rodents
              
 12:30
Lunch Break, Poster Viewing and Visit the Exhibition

 13:30 Session IV: Tools for Approaching Metabesity
   
Nutritional Biochemistry and Aging

Vitamin D and Obesity
Jenny GuntonChair of Medicine, University of Sydney, Westmead Hospital, Australia

Neuroinflammation - Using Big Data to Inform Clinical Practice
Lars FuggerWeatherall Institute of Molecular Medicine, Oxford, UK

Interactions between Genetic, Lifestyle/Environmental Risk Factors for Multiple Sclerosis
Tomas Olsson
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden  

 15:00
Coffee Break, Poster Viewing and Visit the Exhibition

 15:30 Session V: Metabesity Interventions under Development
 
Clinical Studies of mTORC1 Compounds

Diabetes Prevention, What have we Learned from DPT et al?
Itamar RazHadassah Medical School at the Hebrew University of JerusalemIsrael

Qualifying Clinical Candidates for Anti-Aging Interventions
Nir BarzilaiAlbert Einstein College of Medicine, NY, USA

Hepatic Steatosis, What do NASH trials teach us?
Brian HarveyExecutive Vice President, Scientific and Regulatory Affairs at the non-profit Global Liver Institute, USA

Targeting Aging with Metformin - Proof of Concept
Steve KritchevskyWake Forest Baptist Medical Center, Winston-Salem, USA


  17:30  
End of Day One


Tuesday, 31 October

 07:30 Registration 
 08:30 Session VI: Tall Orders for Evidence — Clinical, Regulatory, Ethical, Economic
 
Clinical Evidence Aimed at the Regulators
Philip Home, Professor of Diabetes Medicine, Newcastle University, UK

Regulatory Perspectives (invited)

“What Evidence Do Payers Need and What Can We Pay?  
Gillian Leng, Deputy Chief Executive, National Institute for Health and Care Excellence, UK
Barry Straube, National Healthcare Policy, Quality, Clinical/Academic Expert, USA

Ethics for an Age of “Metabesity”?
Joshua Hordern, Associate Professor of Christian Ethics, Faculty of Theology and Religion, University of Oxford, UK

Voice of the Would Be Non-Patient
Julia Manning, Founding Director, 2020health, UK (Co-Chair)


 10:30
Coffee Break, Poster Viewing and Visit the Exhibition

  Session VII: Solutions 
  a. It’s a Drug
  • Big Pharma can/should do this (invited)
b. It’s a Nutritional
  • The Science is there (invited)
  • Addressing sarcopenia today and tomorrow
c. It’s an App

We are on it
Stephanie Tilenius, Co-Founder and CEO, Vida Health, USA

d. It’s Something Else 

Lucy Rose
,
Lucy Rose & Associates, USA

 12:30

Lunch Break, Poster Viewing and Visit the Exhibition

 13:30 Session VII: Solutions (continued)
 
e. Financing (Capital Markets, Philanthropy, Public Funding) 

Roundtable

f. Commercialization
Roundtable
Joseph C. Cook, Jr., Executive Chairman of the Board & President, NuSirt Biopharma, USA

 15:00

Coffee Break, Poster Viewing and Visit the Exhibition

 15:30 Session VIII: Where Do We Go From Here
 
Panel and Round Table Discussion

Moderators:  Julia Manning, Founding Director, 2020health, UK (Co-Chair)
                      Thomas Seoh, President and Chief Executive Officer, Kinexum, USA

a. What are some priority scientific shots?
b. Is there a clinical trial template for Metabesity agents?
c. Can regulators offer some pathways?
d. Will payers pay?
e. Will the people come?


  16:30
 End of Congress